Other approaches are being developed to improve the antitumor activity of EBV-specific T cells including genetic approaches to enhance the resistance of these cells toward the immunosuppressive tumor microenvironment, in addition to combination approaches with other immune-modulating modalities (immune checkpoints such as CTLA-4 blockade or PD-1/PD-L1 blockade) (135). This evidence concerns the gene CD274 and neoplasm.